PPAR- γ agonist in treatment of diabetes: Cardiovascular safety considerations

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 10, Issue 2, 2012, Pages 124-134

  Abbas, Aamer ^a   Blandon, Jimena ^a   Rude, Jennifer ^a   Elfar, Ahmed ^a   Mukherjee, Debabrata ^a  

^a Paul L Foster School of Medicine   (United States)

Author keywords

Bladder Cancer; Bone Loss; Cardiovascular Diseases; Diabetes; Edema; Heart Failure; Insulin Resistance; Pioglitazone; PPAR Agonist; Prediabetes; Rosiglitazone; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYTOKINE; FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; TROGLITAZONE;

ARTICLE; BLADDER CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; INSULIN RESISTANCE; LIPID TRANSPORT; LIVER TOXICITY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; SIDE EFFECT; WEIGHT GAIN;

EID: 84860447679     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152512800388948     Document Type: Article

References (51)

1. Henry, R.R. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin. Ther., 2003, 25(Suppl. B), B47-B63.
2. Fernandez-Real, J.M.; Pickup, J.C. Innate immunity, insulin resistance and type 2 diabetes. Diabetologia, 2012, 55(2), 273-278.
3. Edelman, S.V. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. Rev. Cardiovasc. Med., 2003, 4(Suppl. 6), S29-S37.
4. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2004, 27(Suppl. 1), S5-S10.
5. Lakka, H.M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002, 288(21), 2709-2716.
6. Henry, R.R. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann. Intern. Med., 1996, 124(1 Pt. 2), 97-103.
7. Basu, R.; Chandramouli, V.; Dicke, B.; Landau, B.; Rizza, R. Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes, 2005, 54(7), 1942-1948.
8. Haffner, S.M. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes. Res. Clin. Pract., 2003, 61(Suppl. 1), S9-S18.
9. Barbieri, R.L.; Smith, S.; Ryan, K.J. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil. Steril., 1988, 50(2), 197-212.
10. Yki-Jarvinen, H. Thiazolidinediones. N. Engl. J. Med., 2004, 351(11), 1106-1118.
11. Reusch, J.E. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am. J. Cardiol., 2002, 90(5A), 19G-26G.
12. Haffner, S.M.; Lehto, S.; Ronnemaa, T.; Pyorala, K.; Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 1998, 339(4), 229-234.
13. Hu, G.; Jousilahti, P.; Qiao, Q.; Peltonen, M.; Katoh, S.; Tuomilehto, J. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J. Am. Coll. Cardiol., 2005, 45(9), 1413-1418.
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285(19), 2486-2497.
15. Otten, R.; Kline-Rogers, E.; Meier, D.; Dumasia, R.; Fang, J.; May, N.; Resin, Y.; Armstrong, D.; Saab, F.; Petrina, M.; Eagle, K.; Mukherjee, D. Impact of prediabetic state on clinical outcomes in patients with acute coronary syndromes. Heart, 2005, 91(11), 1466-1468.
16. Consoli, A.; Devangelio, E. Thiazolidinediones and inflammation. Lupus, 2005, 14(9), 794-797.
17. Sakamoto, J.; Kimura, H.; Moriyama, S.; Odaka, H.; Momose, Y.; Sugiyama, Y.; Sawada, H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun., 2000, 278(3), 704-711.
18. Olefsky, J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J. Clin. Invest., 2000, 106(4), 467-472.
19. Wang, M.; Tafuri, S. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J. Cell. Biochem., 2003, 89(1), 38-47.
20. Hsueh, W.A.; Jackson, S.; Law, R.E. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care, 2001, 24(2), 392-397.
21. Momoi, A.; Murao, K.; Imachi, H.; Ishida, T.; Cao, W.M.; Sato, M.; Takahara, J. Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione. Chest, 2001, 120(4), 1293-1300.
22. Panzer, U.; Schneider, A.; Guan, Y.; Reinking, R.; Zahner, G.; Harendza, S.; Wolf, G.; Thaiss, F.; Stahl, R.A. Effects of different PPARgamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis. Kidney Int., 2002, 62(2), 455-464.
23. Nissen, S.E.; Nicholls, S.J.; Wolski, K.; Nesto, R.; Kupfer, S.; Perez, A.; Jure, H.; De Larochelliere, R.; Staniloae, C.S.; Mavromatis, K.; Saw, J.; Hu, B.; Lincoff, A.M.; Tuzcu, E.M. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA, 2008, 299(13), 1561-1573.
24. Gerstein, H.C.; Ratner, R.E.; Cannon, C.P.; Serruys, P.W.; Garcia-Garcia, H.M.; van Es, G.A.; Kolatkar, N.S.; Kravitz, B.G.; Miller, D.M.; Huang, C.; Fitzgerald, P.J.; Nesto, R.W. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation, 2010, 121(10), 1176-1187.
25. Nissen, S.E.; Wolski, K.; Topol, E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA, 2005, 294 (20), 2581-2586.
26. Einhorn, D.; Aroda, V.R.; Henry, R.R., Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol. Metab. Clin. North. Am. 2004, 33(3), 595-616, vii-viii.
27. Lewin, A.J.; Kipnes, M.S.; Meneghini, L.F.; Plotkin, D.J.; Perevozskaya, I.T.; Shah, S.; Maccubbin, D.L.; Mitchel, Y.B.; Tobert, J.A. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther., 2004, 26(3), 379-389.
28. Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E.; Hamman, R.F.; Lachin, J.M.; Walker, E.A.; Nathan, D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J.Med., 2002, 346(6), 393-403.
29. Buchanan, T.A.; Xiang, A.H.; Peters, R.K.; Kjos, S.L.; Marroquin, A.; Goico, J.; Ochoa, C.; Tan, S.; Berkowitz, K.; Hodis, H.N.; Azen, S.P. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes, 2002, 51(9), 2796-2803.
30. Chilcott, J.; Tappenden, P.; Jones, M.L.; Wight, J.P. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin. Ther., 2001, 23(11), 1792-1823; discussion 1791.
31. Kelly, I.E.; Han, T.S.; Walsh, K.; Lean, M.E. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care., 1999, 22(2), 288-293.
32. Miyazaki, Y.; Mahankali, A.; Matsuda, M.; Mahankali, S.; Hardies, J.; Cusi, K.; Mandarino, L.J.; DeFronzo, R.A., Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab., 2002, 87(6), 2784-2791.
33. Avandia (rosiglitazone maleate) Philadelphia, PA, GlaxoSmith Kline Pharmaceuticals, 2000. 2000-2010.
34. Raskin, P.; Rendell, M.; Riddle, M.C.; Dole, J.F.; Freed, M.I.; Rosenstock, J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care, 2001, 24(7), 1226-1232.
35. Walker, A.B.; Naderali, E.K.; Chattington, P.D.; Buckingham, R.E.; Williams, G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes, 1998, 47(5), 810-814.
36. Nesto, R.W.; Bell, D.; Bonow, R.O.; Fonseca, V.; Grundy, S.M.; Horton, E.S.; Le Winter, M.; Porte, D.; Semenkovich, C.F.; Smith, S.; Young, L.H.; Kahn, R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care, 2004, 27(1), 256-263.
37. Benbow, A.; Stewart, M.; Yeoman, G. Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ, 2001, 322(7280), 236.
38. McDonough, A.K.; Rosenthal, R.S.; Cao, X.; Saag, K.G. The effect of thiazolidinediones on BMD and osteoporosis. Nat. Clin. Pract. Endocrinol. Metab., 2008, 4(9), 507-513.
39. Lecka-Czernik, B., Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr. Osteoporos. Rep., 2010, 8(4), 178-184.
40. Lewis, J.D.; Ferrara, A.; Peng, T.; Hedderson, M.; Bilker, W.B.; Quesenberry, C.P., Jr.; Vaughn, D.J.; Nessel, L.; Selby, J.; Strom, B.L. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care, 2011, 34(4), 916-922.
41. Tseng, C.H. Pioglitazone and Bladder Cancer: A population-based study of Taiwanese. Diabetes Care, 2012, 35(2), 278-280.
42. Gerstein, H.C.; Yusuf, S.; Bosch, J.; Pogue, J.; Sheridan, P.; Dinccag, N.; Hanefeld, M.; Hoogwerf, B.; Laakso, M.; Mohan, V.; Shaw, J.; Zinman, B.; Holman, R.R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 2006, 368(9541), 1096-1105.
43. Home, P.D.; Pocock, S.J.; Beck-Nielsen, H.; Gomis, R.; Hanefeld, M.; Jones, N.P.; Komajda, M.; McMurray, J.J. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N. Engl. J. Med., 2007, 357(1), 28-38.
44. Home, P.D.; Pocock, S.J.; Beck-Nielsen, H.; Curtis, P.S.; Gomis, R.; Hanefeld, M.; Jones, N.P.; Komajda, M.; McMurray, J.J. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 2009, 373(9681), 2125-2135.
45. Komajda, M.; McMurray, J.J.; Beck-Nielsen, H.; Gomis, R.; Hanefeld, M.; Pocock, S.J.; Curtis, P.S.; Jones, N.P.; Home, P.D. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur. Heart. J., 2010, 31(7), 824-831.
46. Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Lefebvre, P.J.; Murray, G.D.; Standl, E.; Wilcox, R.G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R.J.; Koranyi, L.; Laakso, M.; Mokan, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005, 366(9493), 1279-1289.
47. Erdmann, E.; Dormandy, J.A.; Charbonnel, B.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol., 2007, 49(17), 1772-1780.
48. Wilcox, R.; Bousser, M.G.; Betteridge, D.J.; Schernthaner, G.; Pirags, V.; Kupfer, S.; Dormandy, J. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke, 2007, 38 (3), 865-873.
49. Lincoff, A.M.; Wolski, K.; Nicholls, S.J.; Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA, 2007, 298(10), 1180-1188.
50. Loke, Y.K.; Kwok, C.S.; Singh, S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ, 2011, 342, d1309.
51. Krumholz, H.M. A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks. Circ. Cardiovasc. Qual. Outcomes, 2010, 3(3), 221-222.